Zhang Wenxue, Sun Jian, Cao Yongzhen, Yang Xuejun
Department of Radiotherapy, Tianjin Medical University General Hospital, Tianjin 300052, China.
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China, Email:
Zhonghua Yi Xue Za Zhi. 2015 Aug 18;95(31):2522-5.
To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma.
A total of 33 whole-resected patients, 14 partial-resected patients and 3 biopsied patients were randomly divided into limited margins group and routine margins group. The patients were treated with IMRT and temozolomide concurrent chemotherapy, subsequently adjuvant chemotherapy. Then all the patients were evaluated 2 months later after concurrent chemoradiotherapy. Progression-free survival in 1 year (PFS-1), progress free survival rate in 1 year (PFSR-1) and 1 year survival rate (SR-1) were recorded.All the possible prognostic factors were analyzed.
Routine margins group: complete response (CR) 19, partial response (PR) 2, stable disease (SD) 2, progressive disease (PD) 2; Limited margins group: CR 16, PR 6, SD 1, PD 2. Mean PFS-1 of the two groups were 11.64 and 11.36 months, respectively. PFSR-1 were 84% in routine margins group and 80% in limited margins group. SR-1 of two groups were both 100%. Surgery results and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status were correlated with immediate-term prognosis by either univariate or multivariate analysis. Both surgery results and immediate-term prognosis were relevant factors to PFS-1. Progression sites in two groups had no statistical difference by analysis.
Both groups gained favorable results, and limited margins doesn't increase local failures. Surgery results are important prognostic factors to immediate-term prognosis and PFS-1.
评估局限边缘调强放射治疗(IMRT)联合替莫唑胺化疗治疗恶性胶质瘤患者的疗效,并探讨恶性胶质瘤的预后因素。
将33例全切除患者、14例部分切除患者和3例活检患者随机分为局限边缘组和常规边缘组。患者接受IMRT和替莫唑胺同步化疗,随后进行辅助化疗。同步放化疗2个月后对所有患者进行评估。记录1年无进展生存期(PFS-1)、1年无进展生存率(PFSR-1)和1年生存率(SR-1)。分析所有可能的预后因素。
常规边缘组:完全缓解(CR)19例,部分缓解(PR)2例,疾病稳定(SD)2例,疾病进展(PD)2例;局限边缘组:CR 16例,PR 6例,SD 1例,PD 2例。两组的平均PFS-1分别为11.64个月和11.36个月。常规边缘组的PFSR-1为84%,局限边缘组为80%。两组的SR-1均为100%。单因素和多因素分析均显示手术结果和O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化状态与近期预后相关。手术结果和近期预后均是PFS-1的相关因素。两组进展部位分析无统计学差异。
两组均取得良好效果,局限边缘并未增加局部失败率。手术结果是近期预后和PFS-1的重要预后因素。